Virtual Library

Start Your Search

Yeol Kim

Author of

  • +

    Mini Oral session III (ID 65)

    • Event: ELCC 2019
    • Type: Mini Oral session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 4/12/2019, 17:45 - 18:45, Room C
    • +

      42O - Implementation of organized lung cancer screening program in Korea (ID 608)

      17:45 - 18:45  |  Presenting Author(s): Yeol Kim

      • Abstract
      • Presentation
      • Slides


      Lung cancer is the leading cause of cancer mortality worldwide and has a low survival rate due to difficulties cocnerning early detection. The Korean Lung Cancer Screening demonstration project (K-LUCAS) was started in February 2017. K-LUCAS will assess the effectiveness, harm, and feasibility of lung cancer screening in order to implement a population-based screening program. K-LUCAS will evaluate the validation of the new standard of reporting form of low-dose computed tomography (LDCT) and the quality of lung cancer screening by a web-based network system using computer-aided nodule detection program (CAD).

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      K-LUCAS is a population-based single arm trial conducted in 14 cancer hospitals that targets a high-risk population aged 55-74 years with at least 30 pack-year smoking history within the last 15 years. Participants were recruited when visiting the national cancer screening center or smoking cessation clinics based on a lung cancer risk evaluation questionnaire. Lung cancer screening was provided by LDCT with at least a 16-row multidetector CT scanner and screening results were reported by Lung Imaging Reporting and Data System (Lung-RADS). All participants should have their results explained to them by a physician and current smokers should receive smoking cessation counselling.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      Up until November 2018, 13,491 participants had joined K-LUCAS. The positive screening rate (categories 3 and 4 in Lung-RADS) was 15.3%. Among these, 69 lung cancers were detected and stage I and II lung cancers were 53.6% and 15.9%, respectively. CAD detects more positive findings but decreases the variation of positive rate among screening units. About 75% of abnormal findings, including emphysema, coronary artery calcification etc. besides lung nodules, were detected in K-LUCAS.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      K-LUCAS shows promising results in effective detection of early stage lung cancer and controlling diagnosis quality by a web-based network system. Based on the observations from K-LUCAS, a decision will be made as to whether lung cancer screening will be included in national cancer screening program.

      b651e8a99c4375feb982b7c2cad376e9 Clinical trial identification


      7a6a3ffa2dadc03a6151ee2c4d6fa383 Legal entity responsible for the study

      The author.

      213f68309caaa4ccc14d5f99789640ad Funding

      Ministry of Health and Welfare, Republic of Korea.

      682889d0a1d3b50267a69346a750433d Disclosure

      The author has declared no conflicts of interest.


      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.